V
31.80
1.55 (5.12%)
| Previous Close | 30.25 |
| Open | 30.09 |
| Volume | 1,003,630 |
| Avg. Volume (3M) | 990,173 |
| Market Cap | 2,478,644,480 |
| Price / Earnings (TTM) | 102.58 |
| Price / Earnings (Forward) | 20.33 |
| Price / Sales | 4.99 |
| Price / Book | 1.93 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Profit Margin | 7.13% |
| Operating Margin (TTM) | 7.03% |
| Diluted EPS (TTM) | 0.420 |
| Quarterly Revenue Growth (YOY) | 18.20% |
| Total Debt/Equity (MRQ) | 4.23% |
| Current Ratio (MRQ) | 5.10 |
| Operating Cash Flow (TTM) | 89.42 M |
| Levered Free Cash Flow (TTM) | 76.93 M |
| Return on Assets (TTM) | 1.94% |
| Return on Equity (TTM) | 2.86% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Veracyte, Inc. | Bearish | Bullish |
AIStockmoo Score
-0.3
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.25 |
|
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 0.54% |
| % Held by Institutions | 107.98% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Aug 2025 | Announcement | Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference |
| 27 Aug 2025 | Announcement | Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer |
| 26 Aug 2025 | Announcement | Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test |
| 24 Jul 2025 | Announcement | Veracyte Set to Join S&P SmallCap 600 |
| 17 Jul 2025 | Announcement | Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025 |
| 08 Jul 2025 | Announcement | Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |